Objectives: The purpose of present study was to detect serum and salivary levels of apoptotic related marker sFasL in oral lichen planus patients versus healthy controls.Materials and methods: The present study was performed on a total of 25 individuals that were selected from the outpatient clinic of Oral Medicine and Periodontology Department, Faculty of Oral and Dental Medicine, Cairo University. They were divided into 2 groups, 15 patients suffering from OLP as patient's group and 10 individuals as controls. Patients were subjected to full history taking and clinical examination including clinical score for OLP lesions and assessment for degree of pain in exacerbation. Collection of unstimulated whole saliva (WUS) was performed using standard techniques for detection of sFas ligand level. Analysis of salivary samples was done using ELISA kit. Blood samples were collected once from all groups. All blood samples were centrifuged and collected sera was stored at -200C until assayed. The results of salivary sFas ligand level of patients were then compared with those of 10 controls.Results: In the patient’s group, sFasL level in saliva and serum was statistically significant higher than that of controls. However, there was no statistically significant correlation between Fas ligand level in serum and saliva of the same individual. When comparing the mean level of sFasL in serum of subgroup A (atrophic type), B (erosive/ulcerative) and control groups, there was no statistically significant difference between subgroup A and subgroup B; both showed the statistically significantly highest mean sFasL in serum. Control group showed the statistically significantly lowest mean sFasL in serum. However, when comparing the mean level of sFasL in saliva in the three groups, subgroup A showed the statistically significantly highest mean sFasL in saliva. This was followed by subgroup B. Control group showed the statistically significantly lowest mean sFasL in saliva. Conclusion: sFas ligand level in serum and saliva was higher in patients with OLP when compared to controls. Saliva could be considered as sensitive as serum to evaluate the level of sFasL in OLP. The saliva is more sensitive than the serum in monitoring the progression of OLP regarding the variations of sFasL level in different clinical types.